How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

We celebrate 60 years of Mountain Gazette with their editor Mike Rogge. Plus: Josh Riedel on his latest project, Thirty Cabins: Stories and Hywel Mills from The Signal. We speak with Grace O’Neill and ...

CFO Sarah Friar confirmed at Goldman Sachs' Communacopia conference that OpenAI's frontier models helped architect the very ...

View the basic RXRX option chain and compare options of Recursion Pharmaceuticals, Inc. on Yahoo Finance.

Recursion Pharmaceuticals insiders reported 3 transactions totaling $430,930.56. Activity included 2 tax-related share dispositions and 1 stock sale, with no anomalies flagged. View more Major Holders ...